Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sosei Heptares' multi-target pact with Genentech reinforces the company's position as the go-to GPCR platform partner; Roche's James Sabry called Sosei's…
Sosei Heptares achieved an early discovery milestone under the Genentech collaboration, triggering a $3M payment and signaling that the platform was producing…
Sosei Heptares received a $3.75M payment for progression of a 'potential first-in-class project targeting an undisclosed GPCR' under the Genentech multi-target…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sosei Heptares and Genentech (Roche) signed a multi-target research collaboration and license agreement leveraging Sosei's StaR/SBDD GPCR drug-design platform. Sosei received $26M in upfront and near-term payments and is eligible for over $1B in research, development and commercial milestones plus royalties. Genentech receives exclusive global rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Sosei Group Corporation (Sosei Heptares) (this deal) | 2019 | $1.0B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Multiple (undisclosed) deals